nach oben

Erschienen in:

21.06.2021

Impact of lay navigation on utilization and Medicare spending for cancer survivors in the “Deep South”

verfasst von: Courtney P. Williams, Gabrielle B. Rocque, Andres Azuero, Kelly M. Kenzik, Grant R. Williams, Pradeep Sharma, Rodney P. Rocconi, Wendy Demark-Wahnefried, Michelle Y. Martin, Maria Pisu

Erschienen in: Journal of Cancer Survivorship | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Though lay navigation programs have proven beneficial for individuals during cancer treatment, little is known about the effects of lay navigation on health care utilization and Medicare spending among older adults during cancer survivorship.

Methods

This retrospective cohort study used administrative claims data to evaluate a lay navigation program implemented from 2012 to 2015 at 12 academic and community cancer centers in the Southeast. Medicare beneficiaries age ≥65 years navigated during survivorship were compared to propensity score–matched, non-navigated cancer survivors. Quarterly trends in Medicare spending were estimated using repeated measures mixed models. Rate ratios (RRs) and 95% confidence intervals (CIs) were estimated using repeated measures generalized linear models for quarterly emergency room (ER) visits and hospitalizations.

Results

Medicare spending for navigated (n = 3255) versus non-navigated older cancer survivors (n = 3255) was initially higher but declined faster by $513 per patient per quarter (95% CI −$616, −$410). Per patient per quarter risk of ER visits decreased by 11% (RR 0.89, 95% CI 0.86, 0.92) and hospitalizations decreased by 16% (RR 0.84, 95% CI 0.81, 0.88) over time comparing navigated versus non-navigated patients. Similar results were seen for patients enrolled in navigation post-treatment (N = 1893).

Conclusions

In older cancer survivors receiving care in the Deep South, patients receiving lay navigation compared to those non-navigated had significant reductions in Medicare spending, hospitalizations, and ER visits.

Implications for Cancer Survivors

Though much emphasis has been placed on lay navigation during initial cancer treatment, navigation is needed throughout survivorship due to the high costs and health care utilization that persist post-treatment.

Nur mit Berechtigung zugänglich

De Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev. 2013;22(4):561–70. https://doi.org/10.1158/1055-9965.EPI-12-1356.

Society AC. Cancer treatment & survivorship facts & figures 2019–2021. GA: American Cancer Society Atlanta; 2019.

Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758–65. https://doi.org/10.1200/JCO.2008.20.8983.CrossRefPubMed

Vincent GK, Velkoff VA. The next four decades: the older population in the United States: 2010 to 2050, vol. 1138. US: US Department of Commerce, Economics and Statistics Administration; 2010.

Institute of Medicine. Delivering high-quality cancer care: charting a new course for a system in crisis. Washington, DC: The National Academies Press; 2013.

Stanton AL. What happens now? Psychosocial care for cancer survivors after medical treatment completion. J Clin Oncol. 2012;30(11):1215–20. https://doi.org/10.1200/JCO.2011.39.7406.

Pisu M, Azuero A, Halilova KI, Williams CP, Kenzik KM, Kvale EA, et al. Most impactful factors on the health-related quality of life of a geriatric population with cancer. Cancer. 2018;124(3):596–605. https://doi.org/10.1002/cncr.31048.CrossRefPubMed

Baik SH, Gallo LC, Wells KJ. Patient navigation in breast cancer treatment and survivorship: a systematic review. J Clin Oncol. 2016;34(30):3686–96. https://doi.org/10.1200/JCO.2016.67.5454.CrossRefPubMedPubMedCentral

Krok-Schoen JL, Oliveri JM, Paskett ED. Cancer care delivery and women’s health: the role of patient navigation. Front Oncol. 2016;6:2. https://doi.org/10.3389/fonc.2016.00002.CrossRefPubMedPubMedCentral

10.

Ko NY, Snyder FR, Raich PC, Paskett ED, Dudley DJ, Lee JH, et al. Racial and ethnic differences in patient navigation: results from the Patient Navigation Research Program. Cancer. 2016;122(17):2715–22. https://doi.org/10.1002/cncr.30109.CrossRefPubMed

11.

Pisu M, Rocque GB, Jackson BE, Kenzik KM, Sharma P, Williams CP et al. Lay navigation across the cancer continuum for older cancer survivors: equally beneficial for Black and White survivors? J Geriatr Oncol. 2019;10(5):779–86. https://doi.org/10.1016/j.jgo.2018.10.013.

12.

Rocque GB, Partridge EE, Pisu M, Martin MY, Demark-Wahnefried W, Acemgil A, et al. The Patient Care Connect Program: transforming health care through lay navigation. J Oncol Pract. 2016;12(6):e633–42. https://doi.org/10.1200/JOP.2015.008896.CrossRefPubMedPubMedCentral

13.

Rocque GB, Pisu M, Jackson BE, Kvale EA, Demark-Wahnefried W, Martin MY, et al. Resource use and Medicare costs during lay navigation for geriatric patients with cancer. JAMA Oncol. 2017;3(6):817–25. https://doi.org/10.1001/jamaoncol.2016.6307.CrossRefPubMedPubMedCentral

14.

Rocque GB, Mullvain JA, Eickhoff J, Cleary JF, Campbell TC. Integrating palliative care into the oncology clinic: a joint management approach. Palliat Med. 2016;30(5):510–2. https://doi.org/10.1177/0269216315601947.CrossRefPubMed

15.

Rocque GB, Dionne-Odom JN, Sylvia Huang CH, Niranjan SJ, Williams CP, Jackson BE, et al. Implementation and impact of patient lay navigator-led advance care planning conversations. J Pain Symptom Manag. 2017;53(4):682–92. https://doi.org/10.1016/j.jpainsymman.2016.11.012.CrossRef

16.

Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258–67.CrossRef

17.

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRef

18.

Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.CrossRef

19.

Rural-Urban Commuting Area Codes. United States Department of Agriculture. 2016. https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes/.

20.

Mariotto AB, Enewold L, Zhao J, Zeruto CA, Yabroff KR. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomarkers Prev. 2020;29(7):1304–12. https://doi.org/10.1158/1055-9965.EPI-19-1534.

21.

Pergolotti M, Deal AM, Lavery J, Reeve BB, Muss HB. The prevalence of potentially modifiable functional deficits and the subsequent use of occupational and physical therapy by older adults with cancer. J Geriatr Oncol. 2015;6(3):194–201. https://doi.org/10.1016/j.jgo.2015.01.004.

22.

Pergolotti M, Deal AM, Williams GR, Bryant AL, McCarthy L, Nyrop KA et al. Older adults with cancer: a randomized controlled trial of occupational and physical therapy. J Am Geriatr Soc. 2019;67(5):953–60. https://doi.org/10.1111/jgs.15930.

23.

Williams GR, Mackenzie A, Magnuson A, Olin R, Chapman A, Mohile S et al. Comorbidity in older adults with cancer. J Geriatr Oncol. 2016;7(4):249–57. https://doi.org/10.1016/j.jgo.2015.12.002.

24.

Turkman YE, Williams CP, Jackson BE, Dionne-Odom JN, Taylor R, Ejem D, et al. Disparities in hospice utilization for older cancer patients living in the Deep South. J Pain Symptom Manag. 2019;58:86–91. https://doi.org/10.1016/j.jpainsymman.2019.04.006.CrossRef

25.

Kirchhoff KT, Hammes BJ, Kehl KA, Briggs LA, Brown RL. Effect of a disease-specific advance care planning intervention on end-of-life care. J Am Geriatr Soc. 2012;60(5):946–50. https://doi.org/10.1111/j.1532-5415.2012.03917.x.

26.

Rae M, Claxton G, Levitt L. Do health plan enrollees have enough money to pay cost sharing? Kaiser Family Foundation Issue Brief. 2017.

27.

Altice CK, Banegas MP, Tucker-Seeley RD, Yabroff KR. Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst. 2017;109(2). https://doi.org/10.1093/jnci/djw205.

28.

Kaisaeng N, Harpe SE, Carroll NV. Out-of-pocket costs and oral cancer medication discontinuation in the elderly. J Manag Care Spec Pharm. 2014;20(7):669–75. https://doi.org/10.18553/jmcp.2014.20.7.669.CrossRefPubMed

29.

Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32(4):306–11. https://doi.org/10.1200/JCO.2013.52.9123.CrossRefPubMed

30.

Zafar SY, Abernethy AP. Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park). 2013;27(2):80–1 149.

31.

Zafar SY, McNeil RB, Thomas CM, Lathan CS, Ayanian JZ, Provenzale D. Population-based assessment of cancer survivors’ financial burden and quality of life: a prospective cohort study. J Oncol Pract. 2015;11(2):145–50. https://doi.org/10.1200/JOP.2014.001542.CrossRefPubMed

32.

Giri S, Clark D, Al-Obaidi M, Varnado W, Kumar S, Paluri R et al. Financial distress among older adults with cancer. JCO Oncol Pract. 2020:OP. 20.00601. https://doi.org/10.1200/OP.20.00601.

33.

Banegas MP, Guy GP Jr, de Moor JS, Ekwueme DU, Virgo KS, Kent EE, et al. For working-age cancer survivors, medical debt and bankruptcy create financial hardships. Health Aff (Millwood). 2016;35(1):54–61. https://doi.org/10.1377/hlthaff.2015.0830.CrossRef

34.

Shankaran V, Leahy T, Steelquist J, Watabayashi K, Linden H, Ramsey S et al. Pilot feasibility study of an oncology financial navigation program. J Oncol Pract. 2018;14(2):e122–e9. https://doi.org/10.1200/JOP.2017.024927.

35.

Charlton M, Schlichting J, Chioreso C, Ward M, Vikas P. Challenges of rural cancer care in the United States. Oncology (Williston Park). 2015;29(9):633–40.

36.

Weaver KE, Geiger AM, Lu L, Case LD. Rural-urban disparities in health status among US cancer survivors. Cancer. 2013;119(5):1050–7. https://doi.org/10.1002/cncr.27840.

37.

Palmer NR, Avis NE, Fino NF, Tooze JA, Weaver KE. Rural cancer survivors’ health information needs post-treatment. Patient Educ Couns. 2020;103(8):1606–14. https://doi.org/10.1016/j.pec.2020.02.034.

38.

Palomino H, Peacher D, Ko E, Woodruff SI, Watson M. Barriers and challenges of cancer patients and their experience with patient navigators in the rural US/Mexico border region. J Cancer Educ. 2017;32(1):112–8. https://doi.org/10.1007/s13187-015-0906-0.

Titel: Impact of lay navigation on utilization and Medicare spending for cancer survivors in the “Deep South”
verfasst von: Courtney P. Williams
Gabrielle B. Rocque
Andres Azuero
Kelly M. Kenzik
Grant R. Williams
Pradeep Sharma
Rodney P. Rocconi
Wendy Demark-Wahnefried
Michelle Y. Martin
Maria Pisu
Publikationsdatum: 21.06.2021
Verlag: Springer US
Erschienen in: Journal of Cancer Survivorship / Ausgabe 4/2022
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-021-01064-0

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Impact of lay navigation on utilization and Medicare spending for cancer survivors in the “Deep South”